Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Immatics N.V. (IMTX)
USD9.50
+0.15 (+1.60%)
DE NASDAQ Healthcare Biotechnology
Address
Paul-Ehrlich-Strasse 15 72076
Tübingen, DE
Tübingen, DE
CEO
Harpreet Singh
Website
immatics.com
IPO
2018-12-12
CIK 1809196 ISIN NL0015285941
Also trades on
NASDAQ Capital Market · IMTX (USD)
NASDAQ Capital Market · IMTXW (USD)
Description
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.50
+0.15 (+1.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
455.8K
Beta
1.30
Float Shares
112.36M
Free Float %
83.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.52% | +0.36% | +2.01% | +13.52% | +9.51% | +6.38% | +144.96% | +11.25% | +4.20% | +16.35% | +16.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
9.50
Low
17.00
+78.9%
Consensus
21.00
+121.1%
Median
21.00
+121.1%
High
25.00
+163.2%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 10 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
25.00
+163.2%
|
| Last Year | 4 |
19.25
+102.6%
|
| All Time | 6 |
20.17
+112.3%
|
Quality scores
Altman Z-Score
5.94
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-69.0% Q1'26: -58.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-1,200.0% Q1'26: -30.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-481.9% Q1'26: -562.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-409.2% Q1'26: -868.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-650.0% Q1'26: -1,550.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+14.6% Q1'26: +10.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.08× Q1'26: -0.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 6 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 4 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
31.25M
est: 29.30M (+6.7%)
|
34.76M
est: 31.72M (+9.6%)
|
172.83M
est: 152.54M (+13.3%)
|
54.00M
est: 66.04M (-18.2%)
|
155.84M
est: 113.91M (+36.8%)
|
48.27M
est: 39.93M (+20.9%)
|
38.51M
15.60M – 62.92M
-3.5% YoY
|
42.51M
15.02M – 69.99M
+10.4% YoY
|
100.16M
33.74M – 165.49M
+135.6% YoY
|
213.96M
72.09M – 353.53M
+113.6% YoY
|
415.12M
139.86M – 685.91M
+94.0% YoY
|
| EBITDA |
-207.43M
est: -14.59M (-1,322.0%)
|
-87.30M
est: 6.74M (-1,396.1%)
|
50.04M
est: 6.11M (+719.5%)
|
-88.93M
est: -32.88M (-170.5%)
|
34.46M
est: 6.84M (+403.8%)
|
-185.09M
est: -19.88M (-831.1%)
|
-19.17M
-31.32M – -7.77M
+3.5% YoY
|
-21.16M
-34.84M – -7.48M
-10.4% YoY
|
-49.86M
-82.39M – -16.80M
-135.6% YoY
|
-106.53M
-176.01M – -35.89M
-113.6% YoY
|
-206.68M
-341.50M – -69.63M
-94.0% YoY
|
| EBIT |
-211.55M
est: -15.28M (-1,284.6%)
|
-92.77M
est: -879.5K (-10,447.4%)
|
43.07M
est: -797.3K (+5,502.2%)
|
-96.16M
est: -34.44M (-179.2%)
|
22.23M
est: -59.61M (+137.3%)
|
-197.49M
est: -20.82M (-848.5%)
|
-20.08M
-32.81M – -8.14M
+3.5% YoY
|
-22.17M
-36.50M – -7.83M
-10.4% YoY
|
-52.23M
-86.30M – -17.60M
-135.6% YoY
|
-111.58M
-184.36M – -37.59M
-113.6% YoY
|
-216.48M
-357.69M – -72.94M
-94.0% YoY
|
| Net Income |
-229.35M
est: -442.38M (+48.2%)
|
-95.06M
est: 2.93M (-3,346.7%)
|
37.51M
est: -72.00M (+152.1%)
|
-96.99M
est: -68.69M (-41.2%)
|
15.22M
est: -63.81M (+123.8%)
|
-196.45M
est: -186.28M (-5.5%)
|
-202.77M
-241.39M – -131.16M
-8.9% YoY
|
-204.52M
-220.42M – -184.87M
-0.9% YoY
|
-199.02M
-205.09M – -150.86M
+2.7% YoY
|
-126.78M
-234.29M – -17.50M
+36.3% YoY
|
-20.30M
-37.51M – -2.80M
+84.0% YoY
|
| SGA |
34.19M
est: 19.23M (+77.8%)
|
33.81M
est: 879.5K (+3,743.8%)
|
36.12M
est: 797.3K (+4,430.5%)
|
38.20M
est: 42.89M (-10.9%)
|
46.45M
est: 74.24M (-37.4%)
|
51.18M
est: 25.93M (+97.4%)
|
25.01M
10.13M – 40.86M
-3.5% YoY
|
27.61M
9.76M – 45.46M
+10.4% YoY
|
65.05M
21.92M – 107.48M
+135.6% YoY
|
138.97M
46.82M – 229.62M
+113.6% YoY
|
269.62M
90.84M – 445.50M
+94.0% YoY
|
| EPS |
-4.78
est: -4.14 (-15.4%)
|
-1.51
est: -1.51 (-0.1%)
|
0.55
est: 0.64 (-14.1%)
|
-1.20
est: -0.74 (-61.6%)
|
0.14
est: -0.65 (+121.4%)
|
-1.54
est: -1.66 (+7.3%)
|
-1.70
-1.97 – -1.07
-2.3% YoY
|
-1.70
-1.80 – -1.51
+0.1% YoY
|
-1.52
-1.68 – -1.23
+10.7% YoY
|
-1.04
-1.91 – -0.14
+31.6% YoY
|
-0.17
-0.31 – -0.02
+84.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-233.47M
OE per share TTM
-1.90
Owner's Yield
-16.05%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
47.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
16.75M
Insider transactions (90d)
1
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DH-Capital GmbH & Co. KG | 17.20M | 27.30% | — | 17.20M | — | 17.20M | OO | Germany | 2022-02-11 | ↗ |
| 2 | Daniel Hopp | 17.20M | 27.30% | — | 17.20M | — | 17.20M | IN | Germany | 2022-02-11 | ↗ |
| 3 | Dietmar Hopp | 17.20M | 27.30% | — | 17.20M | — | 17.20M | IN | Germany | 2022-02-11 | ↗ |
| 4 | Dr. Mathias Hothum | 17.20M | 27.30% | — | 17.20M | — | 17.20M | IN | Germany | 2022-02-11 | ↗ |
| 5 | OH Beteiligungen GmbH & Co. KG | 17.20M | 27.30% | — | 17.20M | — | 17.20M | OO | Germany | 2022-02-11 | ↗ |
| 6 | Oliver Hopp | 17.20M | 27.30% | — | 17.20M | — | 17.20M | IN | Germany | 2022-02-11 | ↗ |
| 7 | Prof. Dr. Christof Hettich | 17.20M | 27.30% | — | 17.20M | — | 17.20M | IN | Germany | 2022-02-11 | ↗ |
| 8 | Prof. Dr. Friedrich von Bohlen und Halbach | 17.20M | 27.30% | — | 17.20M | — | 17.20M | IN | Germany | 2022-02-11 | ↗ |
| 9 | dievini Hopp BioTech holding GmbH & Co. KG | 17.20M | 27.30% | — | 17.20M | — | 17.20M | OO | Germany | 2022-02-11 | ↗ |
| 10 | Beteiligungen GmbH & Co. KG | 16.48M | 26.20% | — | 16.48M | — | 16.48M | OO | Germany | 2021-02-12 | ↗ |
| 11 | Dr. Christof Hettich | 16.48M | 26.20% | — | 16.48M | — | 16.48M | IN | Germany | 2021-02-12 | ↗ |
| 12 | Dr. Friedrich von Bohlen und Halbach | 16.48M | 26.20% | — | 16.48M | — | 16.48M | IN | Germany | 2021-02-12 | ↗ |
| 13 | GmbH & Co. KG | 16.48M | 26.20% | — | 16.48M | — | 16.48M | OO | Germany | 2021-02-12 | ↗ |
| 14 | Hopp | 16.48M | 26.20% | — | 16.48M | — | 16.48M | IN | Germany | 2021-02-12 | ↗ |
| 15 | Hopp BioTech holding GmbH & Co. KG | 16.48M | 26.20% | — | 16.48M | — | 16.48M | OO | Germany | 2021-02-12 | ↗ |
| 16 | Mathias Hothum | 16.48M | 26.20% | — | 16.48M | — | 16.48M | IN | Germany | 2021-02-12 | ↗ |
| 17 | RTW Investments, LP | 10.00M | 9.70% | — | 10.00M | — | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 18 | Roderick Wong, M.D. | 10.00M | 9.70% | — | 10.00M | — | — | HC, IN | United States | 2024-11-14 | ↗ |
| 19 | Joseph Edelman | 9.47M | 7.90% | — | 9.47M | — | 9.47M | IN | — | 2024-10-17 | ↗ |
| 20 | Perceptive Advisors LLC | 9.47M | 7.90% | — | 9.47M | — | 9.47M | OO | — | 2024-10-17 | ↗ |
| 21 | Perceptive Life Sciences Master Fund, Ltd. | 9.38M | 7.90% | — | 9.38M | — | 9.38M | CO | — | 2024-10-17 | ↗ |
| 22 | 85-4328500 | 7.38M | 7.20% | 7.35M | — | 7.38M | — | IA | Maryland | 2024-11-14 | ↗ |
| 23 | Wellington Group Holdings LLP | 5.96M | 7.82% | — | 5.26M | — | — | HC | Delaware | 2023-02-07 | ↗ |
| 24 | Wellington Investment Advisors Holdings LLP | 5.96M | 7.82% | — | 5.26M | — | — | HC | Delaware | 2023-02-07 | ↗ |
| 25 | Wellington Management Group LLP | 5.96M | 7.82% | — | 5.26M | — | — | HC | Massachusetts | 2023-02-07 | ↗ |
| 26 | Wellington Management Company LLP | 5.62M | 7.37% | — | 5.21M | — | — | IA | Delaware | 2023-02-07 | ↗ |
| 27 | AT Impf GmbH | 4.91M | 6.40% | — | 4.91M | — | 4.91M | OO | Germany | 2023-08-16 | ↗ |
| 28 | ATHOS KG | 4.91M | 6.40% | — | 4.91M | — | 4.91M | OO | Germany | 2023-08-16 | ↗ |
| 29 | Thomas Maier | 4.91M | 6.40% | — | 4.91M | — | 4.91M | IN | Germany | 2023-08-16 | ↗ |
| 30 | Daniel Mack | 3.99M | 6.20% | — | 3.99M | — | — | HC | MA | 2022-02-14 | ↗ |
| 31 | Nantahala Capital Management, LLC | 3.99M | 6.20% | — | 3.99M | — | — | IA | MA | 2022-02-14 | ↗ |
| 32 | Wilmot B. Harkey | 3.99M | 6.20% | — | 3.99M | — | — | HC | MA | 2022-02-14 | ↗ |
| 33 | ARYA Sciences Holdings | 3.50M | 5.60% | — | 3.50M | — | 3.50M | CO | — | 2021-02-16 | ↗ |
| 34 | DH-LT-Investments GmbH | 726.3K | 1.20% | — | 726.3K | — | 726.3K | OO | Germany | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-72 vs prev Q
New positions
2
Closed positions
71
Increased
3
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 80.0K +80.0K (+100.0%) | 840.00M +840.0M (+100.0%) | 0.07% +0.066 pp | 0.96% +0.961 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 2 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 21.46M +2.1M (+10.7%) | 225.32M +60.2M (+36.4%) | 17.65% +1.706 pp | 0.14% +0.041 pp | USD8.16 +28.7% | 11 qtrs — |
| 3 | BAKER BROS. ADVISORS LP | 12.09M +— (+0.0%) | 126.99M +23.9M (+23.2%) | 9.95% -0.001 pp | 0.74% -0.001 pp | USD8.89 +18.1% | 22 qtrs — |
| 4 | RTW INVESTMENTS, LP | 11.43M +2.6M (+29.7%) | 120.05M +44.9M (+59.8%) | 9.41% +2.153 pp | 1.20% +0.277 pp | USD10.18 +3.1% | 22 qtrs — |
| 5 | SUVRETTA CAPITAL MANAGEMENT, LLC | 11.19M -840.0K (-7.0%) | 117.50M +15.0M (+14.6%) | 9.21% -0.692 pp | 2.41% -0.217 pp | USD5.81 +80.7% | 8 qtrs — |
| 6 | PERCEPTIVE ADVISORS LLC | 10.38M +1.0M (+10.7%) | 109.03M +29.1M (+36.4%) | 8.54% +0.822 pp | 1.94% -0.365 pp | USD10.50 +0.0% | 22 qtrs — |
| 7 | VESTAL POINT CAPITAL, LP | 6.13M -225.0K (-3.5%) | 64.31M +10.2M (+18.9%) | 5.04% -0.186 pp | 2.19% -0.257 pp | USD8.99 +16.8% | 9 qtrs — |
| 8 | JEFFERIES FINANCIAL GROUP INC. | 5.06M +3.9M (+323.4%) | 53.13M +42.9M (+421.8%) | 4.16% +3.179 pp | 0.27% +0.223 pp | USD10.03 +4.7% | 2 qtrs — |
| 9 | SOFINNOVA INVESTMENTS, INC. | 3.44M +1.2M (+54.2%) | 36.07M +17.1M (+90.0%) | 2.83% +0.993 pp | 1.56% +0.518 pp | USD7.21 +45.6% | 22 qtrs — |
| 10 | MORGAN STANLEY | 2.09M -115.5K (-5.2%) | 21.94M +3.2M (+16.8%) | 1.72% -0.095 pp | 0.00% +0.000 pp | USD6.76 +55.3% | 22 qtrs — |
| 11 | POINT72 ASSET MANAGEMENT, L.P. | 1.75M +1.6M (+1,384.2%) | 18.42M +17.4M (+1,729.1%) | 1.44% +1.346 pp | 0.02% +0.019 pp | USD10.37 +1.3% | 2 qtrs — |
| 12 | CITADEL ADVISORS LLC | 1.71M +1.1M (+184.3%) | 18.01M +12.9M (+250.4%) | 1.41% +0.915 pp | 0.00% +0.002 pp | USD9.38 +11.9% | 19 qtrs — |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 1.64M +123.0K (+8.1%) | 17.17M +4.3M (+33.3%) | 1.35% +0.101 pp | 0.00% +0.001 pp | USD9.85 +6.6% | 14 qtrs — |
| 14 | WOODLINE PARTNERS LP | 1.00M -841.0K (-45.7%) | 10.51M -5.2M (-33.0%) | 0.82% -0.692 pp | 0.04% -0.033 pp | USD7.57 +38.7% | 12 qtrs — |
| 15 | LYNX1 CAPITAL MANAGEMENT LP | 922.0K +922.0K (+100.0%) | 9.68M +9.7M (+100.0%) | 0.76% +0.758 pp | 1.96% +1.960 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 16 | SPHERA FUNDS MANAGEMENT LTD. | 861.1K +278.0K (+47.7%) | 9.04M +4.1M (+82.0%) | 0.71% +0.229 pp | 1.75% +0.700 pp | USD10.84 -3.1% | 18 qtrs — |
| 17 | LOGOS GLOBAL MANAGEMENT LP | 850.0K +850.0K (+100.0%) | 8.93M +8.9M (+100.0%) | 0.70% +0.699 pp | 0.54% +0.539 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 18 | ALYESKA INVESTMENT GROUP, L.P. | 789.2K +489.2K (+163.1%) | 8.29M +5.7M (+224.2%) | 0.65% +0.402 pp | 0.02% +0.016 pp | USD9.75 +7.7% | 2 qtrs — |
| 19 | PRICE T ROWE ASSOCIATES INC /MD/ | 748.0K +23.2K (+3.2%) | 7.86M +1.7M (+27.2%) | 0.62% +0.019 pp | 0.00% +0.000 pp | USD8.58 +22.4% | 2 qtrs — |
| 20 | ABRDN PLC | 714.6K -74.9K (-9.5%) | 7.50M +776.9K (+11.6%) | 0.59% -0.062 pp | 0.01% +0.001 pp | USD7.28 +44.2% | 6 qtrs — |
| 21 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | 697.4K +— (+0.0%) | 7.32M +1.4M (+23.2%) | 0.57% +0.000 pp | 1.04% +0.175 pp | USD10.61 -1.0% | 22 qtrs — |
| 22 | STEMPOINT CAPITAL LP | 610.3K +610.3K (+100.0%) | 6.41M +6.4M (+100.0%) | 0.50% +0.502 pp | 1.10% +1.099 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 23 | BALYASNY ASSET MANAGEMENT L.P. | 592.4K +592.4K (+100.0%) | 6.22M +6.2M (+100.0%) | 0.49% +0.487 pp | 0.01% +0.008 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 24 | UBS GROUP AG | 563.5K +214.1K (+61.3%) | 5.92M +2.9M (+98.8%) | 0.46% +0.176 pp | 0.00% +0.001 pp | USD7.86 +33.6% | 20 qtrs — |
| 25 | CAPTION MANAGEMENT, LLC | 550.9K +550.9K (+100.0%) | 5.78M +5.8M (+100.0%) | 0.45% +0.453 pp | 0.04% +0.040 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 26 | WASATCH ADVISORS LP | 515.1K -203.8K (-28.3%) | 5.41M -716.2K (-11.7%) | 0.42% -0.168 pp | 0.03% -0.001 pp | USD9.39 +11.8% | 8 qtrs — |
| 27 | TD ASSET MANAGEMENT INC | 500.7K +116.9K (+30.5%) | 5.26M +2.0M (+60.8%) | 0.41% +0.096 pp | 0.00% +0.002 pp | USD9.94 +5.6% | 14 qtrs — |
| 28 | STATE STREET CORP | 444.7K +226.2K (+103.5%) | 4.67M +2.8M (+150.8%) | 0.37% +0.186 pp | 0.00% +0.000 pp | USD9.92 +5.8% | 12 qtrs — |
| 29 | SCHRODER INVESTMENT MANAGEMENT GROUP | 402.4K -25.6K (-6.0%) | 4.05M +666.3K (+19.7%) | 0.33% -0.021 pp | 0.00% +0.001 pp | USD10.01 +4.9% | 8 qtrs — |
| 30 | GOLDMAN SACHS GROUP INC | 323.0K +132.3K (+69.3%) | 3.39M +1.8M (+108.7%) | 0.27% +0.109 pp | 0.00% +0.000 pp | USD8.60 +22.1% | 22 qtrs — |
| 31 | DAFNA CAPITAL MANAGEMENT LLC | 261.1K +26.1K (+11.1%) | 2.74M +739.7K (+36.9%) | 0.21% +0.022 pp | 0.64% +0.142 pp | USD9.35 +12.3% | 9 qtrs — |
| 32 | SG AMERICAS SECURITIES, LLC | 208.5K +208.5K (+100.0%) | 2.19M +2.2M (+100.0%) | 0.17% +0.172 pp | 0.00% +0.003 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 33 | VERITION FUND MANAGEMENT LLC | 206.6K +161.4K (+357.0%) | 2.17M +1.8M (+463.2%) | 0.17% +0.133 pp | 0.01% +0.007 pp | USD10.07 +4.3% | 2 qtrs — |
| 34 | NORTHERN TRUST CORP | 203.4K -11.1K (-5.2%) | 2.14M +308.2K (+16.9%) | 0.17% -0.009 pp | 0.00% +0.000 pp | USD6.48 +62.0% | 17 qtrs — |
| 35 | MONASHEE INVESTMENT MANAGEMENT LLC | 160.3K +160.3K (+100.0%) | 1.68M +1.7M (+100.0%) | 0.13% +0.132 pp | 0.95% +0.949 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 36 | BURKEHILL GLOBAL MANAGEMENT, LP | 150.0K +150.0K (+100.0%) | 1.58M +1.6M (+100.0%) | 0.12% +0.123 pp | 0.10% +0.104 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 37 | QUBE RESEARCH & TECHNOLOGIES LTD | 147.3K -7.4K (-4.8%) | 1.55M +228.4K (+17.3%) | 0.12% -0.006 pp | 0.00% +0.000 pp | USD5.52 +90.2% | 9 qtrs — |
| 38 | JPMORGAN CHASE & CO | 147.0K +11.0K (+8.1%) | 1.54M +384.9K (+33.2%) | 0.12% +0.009 pp | 0.00% +0.000 pp | USD9.25 +13.5% | 20 qtrs — |
| 39 | GEODE CAPITAL MANAGEMENT, LLC | 134.8K +66.0K (+96.1%) | 1.42M +829.4K (+141.6%) | 0.11% +0.054 pp | 0.00% +0.000 pp | USD10.96 -4.2% | 22 qtrs — |
| 40 | MYDA ADVISORS LLC | 120.0K +— (+0.0%) | 1.26M +237.6K (+23.2%) | 0.10% +0.000 pp | 0.24% +0.019 pp | USD5.38 +95.2% | 3 qtrs — |
| 41 | BNP PARIBAS ARBITRAGE, SNC | 116.6K -5.9K (-4.8%) | 1.22M +181.0K (+17.3%) | 0.10% -0.005 pp | 0.00% +0.000 pp | USD6.25 +68.0% | 5 qtrs — |
| 42 | ALPS ADVISORS INC | 110.1K +110.1K (+100.0%) | 1.16M +1.2M (+100.0%) | 0.09% +0.091 pp | 0.01% +0.007 pp | USD10.50 +0.0% | 3 qtrs — |
| 43 | JANE STREET GROUP, LLC | 104.9K +104.9K (+100.0%) | 1.10M +1.1M (+100.0%) | 0.09% +0.086 pp | 0.00% +0.000 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 44 | SUMMITTX CAPITAL, L.P. | 96.8K +52.3K (+117.7%) | 1.02M +637.4K (+168.2%) | 0.08% +0.043 pp | 0.03% +0.015 pp | USD8.15 +28.8% | 3 qtrs — |
| 45 | MILLENNIUM MANAGEMENT LLC | 83.1K -638.7K (-88.5%) | 872.8K -5.3M (-85.8%) | 0.07% -0.526 pp | 0.00% -0.002 pp | USD8.49 +23.7% | 22 qtrs — |
| 46 | SECTORAL ASSET MANAGEMENT INC | 63.0K -497.5K (-88.8%) | 661.7K -4.1M (-86.1%) | 0.05% -0.409 pp | 0.53% -2.417 pp | USD6.66 +57.7% | 3 qtrs — |
| 47 | CITIGROUP INC | 56.4K +56.4K (+100.0%) | 591.9K +591.9K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.000 pp | USD10.50 +0.0% | 22 qtrs — |
| 48 | TUDOR INVESTMENT CORP ET AL | 54.7K +54.7K (+100.0%) | 574.6K +574.6K (+100.0%) | 0.05% +0.045 pp | 0.00% +0.001 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 49 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 55.3K +8.5K (+18.2%) | 556.9K +158.1K (+39.7%) | 0.05% +0.007 pp | 0.00% +0.000 pp | USD8.82 +19.0% | 2 qtrs — |
| 50 | JUMP FINANCIAL, LLC | 50.9K +50.9K (+100.0%) | 534.1K +534.1K (+100.0%) | 0.04% +0.042 pp | 0.01% +0.007 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 51 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 49.4K +1.7K (+3.7%) | 518.4K +112.6K (+27.7%) | 0.04% +0.001 pp | 0.01% +0.001 pp | USD5.79 +81.3% | 3 qtrs — |
| 52 | IKARIAN CAPITAL, LLC | 48.6K -827.0 (-1.7%) | 510.0K +89.1K (+21.2%) | 0.04% -0.001 pp | 0.04% -0.003 pp | USD5.38 +95.2% | 3 qtrs — |
| 53 | LONGAEVA PARTNERS L.P. | 44.6K +44.6K (+100.0%) | 468.3K +468.3K (+100.0%) | 0.04% +0.037 pp | 0.04% +0.039 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 54 | MERCER GLOBAL ADVISORS INC /ADV | 30.0K +— (+0.0%) | 314.9K +59.4K (+23.2%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD11.52 -8.9% | 19 qtrs — |
| 55 | BARCLAYS PLC | 28.2K +26.8K (+1,865.5%) | 295.9K +279.6K (+1,708.7%) | 0.02% +0.022 pp | 0.00% +0.000 pp | USD10.20 +2.9% | 12 qtrs — |
| 56 | VIRTUS INVESTMENT ADVISERS, INC. | 26.5K +8.0K (+43.0%) | 278.2K +120.3K (+76.2%) | 0.02% +0.007 pp | 0.08% +0.030 pp | USD6.80 +54.4% | 4 qtrs — |
| 57 | BLACKROCK, INC. | 25.6K -211.0K (-89.2%) | 268.3K -1.7M (-86.7%) | 0.02% -0.174 pp | 0.00% +0.000 pp | USD10.75 -2.3% | 6 qtrs — |
| 58 | J. GOLDMAN & CO LP | 22.8K +— (+0.0%) | 239.3K +45.1K (+23.2%) | 0.02% +0.000 pp | 0.01% +0.001 pp | USD11.05 -5.0% | 8 qtrs — |
| 59 | AQUATIC CAPITAL MANAGEMENT LLC | 20.2K +20.2K (+100.0%) | 212.3K +212.3K (+100.0%) | 0.02% +0.017 pp | 0.01% +0.006 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 60 | GRAHAM CAPITAL MANAGEMENT, L.P. | 19.6K +19.6K (+100.0%) | 206.1K +206.1K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.005 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 61 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 17.0K -15.0K (-46.9%) | 177.2K -95.1K (-34.9%) | 0.01% -0.012 pp | 0.00% 0.000 pp | USD9.35 +12.3% | 7 qtrs — |
| 62 | GUGGENHEIM CAPITAL LLC | 16.4K +124.0 (+0.8%) | 172.2K +33.5K (+24.2%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD6.82 +54.0% | 5 qtrs — |
| 63 | PALE FIRE CAPITAL SE | 16.3K -18.0K (-52.5%) | 170.9K -121.1K (-41.5%) | 0.01% -0.015 pp | 0.01% -0.021 pp | USD10.16 +3.3% | 7 qtrs — |
| 64 | BANK OF AMERICA CORP /DE/ | 13.5K +5.5K (+68.9%) | 142.2K +73.9K (+108.1%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD7.94 +32.2% | 21 qtrs — |
| 65 | MARINER, LLC | 13.4K -145.0 (-1.1%) | 140.7K +25.2K (+21.9%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD5.38 +95.2% | 3 qtrs — |
| 66 | FOX RUN MANAGEMENT, L.L.C. | 12.3K +12.3K (+100.0%) | 129.2K +129.2K (+100.0%) | 0.01% +0.010 pp | 0.02% +0.020 pp | USD10.50 +0.0% | 3 qtrs — |
| 67 | XTX TOPCO LTD | 11.2K -208.0 (-1.8%) | 118.0K +20.5K (+21.0%) | 0.01% 0.000 pp | 0.00% -0.002 pp | USD8.52 +23.2% | 7 qtrs — |
| 68 | QUARRY LP | 8.0K +8.0K (+100.0%) | 84.0K +84.0K (+100.0%) | 0.01% +0.007 pp | 0.01% +0.013 pp | USD10.50 +0.0% | 1 qtrs NEW |
| 69 | ADVISOR GROUP HOLDINGS, INC. | 5.2K -162.0 (-3.0%) | 54.3K +26.6K (+95.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD8.32 +26.2% | 14 qtrs — |
| 70 | WELLS FARGO & COMPANY/MN | 651.00 +637.0 (+4,550.0%) | 6.8K +6.7K (+5,644.5%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD10.53 -0.3% | 7 qtrs — |
| 71 | FARTHER FINANCE ADVISORS, LLC | 528.00 +193.0 (+57.6%) | 5.5K +2.7K (+94.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.25 +44.8% | 3 qtrs — |
| 72 | NEWEDGE ADVISORS, LLC | 100.00 +— (+0.0%) | 1.1K +198.0 (+23.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.26 +27.1% | 8 qtrs — |
| 73 | SBI SECURITIES CO., LTD. | 25.00 +— (+0.0%) | 263.00 +50.0 (+23.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.08 +48.3% | 5 qtrs — |
| 74 | CLEARSTEAD ADVISORS, LLC | 25.00 +25.0 (+100.0%) | 261.00 +261.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.48 +0.2% | 1 qtrs NEW |
| 75 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 17.00 +17.0 (+100.0%) | 178.00 +178.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.47 +0.3% | 4 qtrs — |
| 76 | HUNTINGTON NATIONAL BANK | 1.00 +— (+0.0%) | 11.00 +2.0 (+22.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.00 +5.0% | 14 qtrs — |
| 77 | TORONTO DOMINION BANK | — -5.1M (-100.0%) | — -43.6M (-100.0%) | 0.00% -4.214 pp | 0.00% -0.068 pp | USD— | 4 qtrs SOLD |
| 78 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -17.2K (-100.0%) | — -146.5K (-100.0%) | 0.00% -0.014 pp | 0.00% +0.000 pp | USD— | 14 qtrs SOLD |
| 79 | READYSTATE ASSET MANAGEMENT LP | — -49.9K (-100.0%) | — -425.5K (-100.0%) | 0.00% -0.041 pp | 0.00% -0.018 pp | USD— | 2 qtrs SOLD |
| 80 | INSIGNEO ADVISORY SERVICES, LLC | — -12.1K (-100.0%) | — -102.8K (-100.0%) | 0.00% -0.010 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
| 81 | HRT FINANCIAL LP | — -67.4K (-100.0%) | — -574.0K (-100.0%) | 0.00% -0.055 pp | 0.00% -0.002 pp | USD— | 4 qtrs SOLD |
| 82 | 683 CAPITAL MANAGEMENT, LLC | — -520.0K (-100.0%) | — -4.4M (-100.0%) | 0.00% -0.428 pp | 0.00% -0.232 pp | USD— | 22 qtrs SOLD |
| 83 | VONTOBEL HOLDING LTD. | — -10.0K (-100.0%) | — -85.2K (-100.0%) | 0.00% -0.008 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 84 | ORBIMED ADVISORS LLC | — -466.6K (-100.0%) | — -4.0M (-100.0%) | 0.00% -0.384 pp | 0.00% -0.094 pp | USD— | 12 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 8 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Tema Oncology ETF CANC | 0.86% | 1.23M | 0.75% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.66% | 1.41M | 0.50% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.64% | 365.6K | 0.65% |
| 4 | State Street SPDR S&P Kensho New Economies Composite ETF KOMP | 0.06% | 1.74M | 0.20% |
| 5 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.06% | 50.9K | 0.89% |
| 6 | State Street SPDR S&P International Small Cap ETF GWX | 0.05% | 453.1K | 0.40% |
| 7 | Fidelity Nasdaq Composite Index ETF ONEQ | 0.01% | 587.6K | 0.21% |
| 8 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 1.87M | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | Hothum Mathias | Director | — | — | Stock Options | 41,500 | 5.44 | 225.8K | 0 | D | ↗ |
| 2026-03-18 | Weinschenk Toni Michael | Officer | — | — | Stock Option (Right to Buy) | 7,850 | 1.06 | 8.3K | 0 | D | ↗ |
| 2026-03-18 | Walter Steffen Martin | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 10,000 | D | ↗ |
| 2026-03-18 | Sturchio Edward A Jr | Officer | — | — | Stock Option (Right to Buy) | 36,000 | 10.00 | 360.0K | 0 | D | ↗ |
| 2026-03-18 | Stone Adam Leo | Director | — | — | Stock Option (Right to Buy) | 25,000 | 10.00 | 250.0K | 0 | D | ↗ |
| 2026-03-18 | Singh Jasuja Harpreet | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 217,241 | D | ↗ |
| 2026-03-18 | Silverstein Jordan Zeik | Officer | — | — | Stock Option (Right to Buy) | 29,000 | 9.68 | 280.7K | 0 | D | ↗ |
| 2026-03-18 | Reinhardt Carsten Alexander Johannes | Officer | — | — | Stock Option (Right to Buy) | 18,753 | 1.06 | 19.9K | 0 | D | ↗ |
| 2026-03-18 | Ramanan Venkat | Officer | — | — | Stock Option (Right to Buy) | 350,000 | 9.00 | 3.15M | 0 | D | ↗ |
| 2026-03-18 | REICIN ALISE | Director | — | — | Stock Option (Right to Buy) | 60,000 | 12.08 | 724.8K | 0 | D | ↗ |
| 2026-03-18 | PERCEPTIVE ADVISORS LLC | Director | — | — | Ordinary Shares, nominal value EUR 0.01 per share | 0 | 0.00 | — | 10,383,456 | I | ↗ |
| 2026-03-18 | Mason Heather L | Director | — | — | Stock Option (Right to Buy) | 25,000 | 10.00 | 250.0K | 0 | D | ↗ |
| 2026-03-18 | Krause Amie Elizabeth | Officer | — | — | Stock Option (Right to Buy) | 211,000 | 10.58 | 2.23M | 0 | D | ↗ |
| 2026-03-18 | Kramer Rainer | Officer | — | — | Stock Option (Right to Buy) | 110,000 | 8.06 | 886.6K | 0 | D | ↗ |
| 2026-03-18 | Forster Eliot | Director | — | — | Stock Option (Right to Buy) | 25,000 | 9.16 | 229.0K | 0 | D | ↗ |
| 2026-03-18 | Chambre Peter Alan | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 105,987 | D | ↗ |
| 2026-03-18 | Carter Paul Rutherford | Director | — | — | Stock Option (Right to Buy) | 25,000 | 10.00 | 250.0K | 0 | D | ↗ |
| 2026-03-18 | Britten Cedrik Michael | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 250 | D | ↗ |
| 2026-03-18 | ATIEH MICHAEL G | Director | — | — | Stock Option (Right to Buy) | 25,000 | 10.00 | 250.0K | 0 | D | ↗ |
| 2026-03-17 | Hothum Mathias | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 329,521 | I | ↗ |
| 2025-06-25 | PERCEPTIVE ADVISORS LLC | Director | — | — | Director Stock Option (Right to Buy) | 40,000 | 12.00 | 480.0K | 0 | I | ↗ |
| 2025-06-25 | Hothum Mathias | Director | — | — | Stock Options | 40,000 | 12.00 | 480.0K | 0 | D | ↗ |
| 2024-06-27 | PERCEPTIVE ADVISORS LLC | Director | — | — | Director Stock Option (Right to Buy) | 25,000 | 11.41 | 285.3K | 0 | I | ↗ |
| 2024-06-27 | Hothum Mathias | Director | — | — | Stock Options | 25,000 | 11.41 | 285.3K | 0 | D | ↗ |
| 2023-06-14 | PERCEPTIVE ADVISORS LLC | Director | — | — | Director Stock Option (Right to Buy) | 25,000 | 7.94 | 198.5K | 0 | I | ↗ |
Executive team
Top executives
EBIT / Employee
-3.6K
Shares Outstanding
134.06M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Harpreet Singh | Chief Executive Officer, MD, Member of Management Board & Executive Director | 1M | — |
| Amie Krause | Chief People Officer | — | female |
| Andrea Mayer Mokler | Vice President & Global Head of Clinical Sciences | — | female |
| Carsten Reinhardt | Chief Development Officer | — | — |
| Dominik Maurer | Senior Vice President & Co-Head of Immatics Discovery Unit | — | male |
| Edward A. Sturchio | General Counsel & Secretary | — | male |
| Ephraim Hofsäß | Vice President of SEC Reporting & Accounting | — | male |
| Hans-Georg Rammensee | Co-Founder & Member of the Scientific Advisory Board | — | — |
| Jason Braun | Senior Vice President Commercial | — | male |
| Lauren Schroeder | Vice President of Marketing | — | female |
| Liane Preussner | Senior Vice President of Clinical Development | — | female |
| Miriam Meyer | Vice President & Global Head of Regulatory Affairs | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
